Xeris Biopharma Holdings

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xeris Biopharma reports record revenue growth and outlines future plans

Xeris Biopharma's Q4 2022 performance reflects strong revenue growth and pipeline advancements, supported by a positive 2023 revenue guidance.
While facing challenges such as competitive pressures and market dynamics, the company's focus on innovation and patient-centric strategies positions them for future success.
Opportunities lie in addressing concerns around product growth, enhancing physician engagement, and pursuing new drug development for long-term growth.

Xeris Biopharma excels in Q1 with strong revenue growth and strategic partnerships

Xeris Biopharma delivered a strong Q1 performance with significant revenue growth, solid product sales, and a healthy cash position, supported by effective financial management.
While facing challenges from potential generic competition and market dynamics, the company's strategic strengths, partnerships, and innovation drive its growth trajectory.
Opportunities in expanding product lines, leveraging partnerships, and investing in R&D position Xeris for continued success and market leadership in the pharmaceutical sector.
Maintaining a balance between addressing challenges, capitalizing on opportunities, and sustaining growth momentum will be key for Xeris Biopharma's future success.

Xeris Biopharma reports record revenue, eyes growth amid challenges

Xeris Biopharma delivered robust Q2 performance, driven by strong revenue growth and key product successes.
While facing challenges like screen failures and patent appeals, the company remains focused on growth opportunities and innovation.
With a solid financial outlook, strategic partnerships, and product advancements, Xeris is poised for continued success and market expansion.

Xeris Biopharma excels in Q3, eyes growth through innovation

Xeris Biopharma delivered a strong Q3 performance with notable revenue growth and a focus on improving cash flow and operational efficiency.
The company's emphasis on innovation, market expansion through subcutaneous drug administration, and management's confidence are key strengths.
Challenges lie in a competitive market landscape and managing investor expectations without providing 2024 financial guidance.
Opportunities include acquisitions, market expansion through innovative drug administration, and attracting institutional investment through improved financial performance.

Xeris Biopharma excels in 2023, eyes sustained growth in 2024

Xeris Biopharma's strong financial performance in 2023, driven by key products and strategic initiatives, positions the company for continued growth.
While facing challenges such as generic competition and market expectations, Xeris remains focused on innovation and market expansion.
Opportunities in revenue growth, market expansion benefits, and patient base increase offer promising prospects for Xeris in 2024.
With a solid foundation of financial prudence, innovation, and growth strategies, Xeris is poised to maintain momentum and drive success in the upcoming year.

Xeris Biopharma reports robust Q1 growth and eyes healthcare partnerships

Xeris Biopharma's Q1 2024 showcased strong financial performance, with revenue growth and strategic collaborations driving optimism for the future. Despite challenges like the cybersecurity breach, the company remains focused on innovation and partnerships to address healthcare needs and reduce hospitalizations.

Xeris Biopharma achieves record revenue, eyes growth amid challenges

Xeris Biopharma's Q3 performance reflects robust revenue growth, strategic focus, and product strength, positioning the company for sustained success.
While challenges like maintaining margins and managing expenses persist, opportunities in communication, partnerships, and new product development offer avenues for future growth.
Investors can be optimistic about Xeris Biopharma's financial stability, growth prospects, and commitment to transparency, despite potential market challenges ahead.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris has rallied substantially off its recent lows as Gvoke sales numbers have been promising.

Xeris Looks Like A High-Quality Platform Play As Gvoke Sales Increase

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and infusible drug formulations, today announced that its Board of Directors has promoted John P.

Xeris Pharmaceuticals Appoints John Shannon President and Chief Operating Officer

Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Xeris Pharmaceuticals (XERS) Stock?

Xeris Pharmaceuticals (XERS) saw a big move last session, as its shares more than 5% on the day, amid huge volumes.

Xeris Pharmaceuticals (XERS) Looks Good: Stock Adds 5.1% in Session

Xeris Pharmaceuticals, Inc. (XERS) CEO Paul Edick on Q2 2020 Results - Earnings Call Transcript

Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 11.27% and -11.18%, respectively, for the quarter ended June 2020.

Xeris Pharmaceuticals, Inc. (XERS) Reports Q2 Loss, Lags Revenue Estimates

Shares of Xeris Pharmaceuticals (NASDAQ:XERS) rose 3% in pre-market trading after the company reported Q2 results.

Recap: Xeris Pharmaceuticals Q2 Earnings

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and infusible drug formulations, today announced financial results for the second quarter and six months ended June 30, 2020, as well as pipeline and corporate highlights.

Xeris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate Highlights

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its second quarter 2020 financial results before the open of the U.S.

Xeris Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced additional data from the Phase 1b study to evaluate a novel diazepam formulation (XP-0863) in healthy adult subjects.

Xeris Pharmaceuticals Announces Additional Data From a Phase 1b Comparative Study of Its Novel Concentrated Diazepam Formulation (XP-0863) and an Expedited Clinical Path Forward

Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Xeris Pharmaceuticals, Inc. (XERS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that, in connection with its previously announced concurrent underwritten public offerings of common stock (the “Shares Offering”) and 5.00% convertible senior notes due 2025 (the “Notes Offering,” together with the Shares Offering, the “Offerings”),

Xeris Pharmaceuticals Announces Full Exercise of Underwriters’ Options to Purchase Additional Shares and Additional Notes

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Gvoke HypoPen™ (glucagon injection) is now available by prescription in the U.S. for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and above. Gvoke HypoPen is the first ready-to-use glucagon i

Xeris Pharmaceuticals Announces Gvoke HypoPen™ – the First Autoinjector for Severe Hypoglycemia – Now Available

Xeris Pharmaceuticals (XERS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Xeris Pharmaceuticals (XERS) in Focus: Stock Moves 6.8% Higher

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the pricing of concurrent underwritten public offerings of 7,400,000 shares of its common stock (the “Shares”) at a public offering price of $2.72 per share for gross proceeds of approximately $20.1 million, and $75.0 million aggregate principal amou

Xeris Pharmaceuticals Announces Pricing of Public Offerings of $20 Million of Common Stock and $75 Million of 5.00% Convertible Senior Notes Due 2025

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has commenced concurrent underwritten public offerings of $20,000,000 in shares of its common stock (the “Shares”) and $60,000,000 aggregate principal amount of convertible senior notes due 2025 (the “Notes”). In addition, Xeris expects to gr

Xeris Pharmaceuticals Announces Proposed Public Offerings of $20 Million of Common Stock and $60 Million of Convertible Senior Notes

Xeris Pharmaceuticals' (XERS) CEO Paul Edick on Q1 2020 Results - Earnings Call Transcript

Xeris Pharmaceuticals Inc (XERS) delivered earnings and revenue surprises of 3.26% and -7.91%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Xeris Pharmaceuticals Inc (XERS) Reports Q1 Loss, Lags Revenue Estimates

As of late, it has definitely been a great time to be an investor in Xeris Pharmaceuticals.

Xeris' Shares March Higher, Can It Continue?

Xeris Pharmaceuticals, Inc.'s (XERS) CEO Paul Edick on Q4 2019 Results - Earnings Call Transcript

Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 0.81% and 144.30%, respectively, for the quarter ended December 2019.

Xeris Pharmaceuticals, Inc. (XERS) Reports Q4 Loss, Tops Revenue Estimates

Analysts Estimate Xeris Pharmaceuticals, Inc. (XERS) to Report a Decline in Earnings: What to Look Out for

CHICAGO, Feb.  11, 2020  (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a public offering price of $4.15 per share, before underwriting discounts and commissions and other offering expenses, for gross proceeds of approximately $37.4 million.  All shares of common stock will be offered by Xeris.  The Company has also granted the underwriters a 30-day option to purchase from the Company up to an additional 1,350,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on February 14, 2020, subject to customary closing conditions. 

Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock

CHICAGO, Feb.  10, 2020  (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All shares of common stock will be offered by Xeris. Xeris expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Xeris Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of Common Stock

Xeris Pharmaceuticals Inc (NASDAQ: XERS) shares are advancing on above-average volume Tuesday following a positive data readout from the company.

News for Xeris Biopharma Holdings Stock (XERS)